P
ARVN icon

Pfizer’s Arvinas ARVN Stock Holding History

Pfizer’s Portfolio ARVN Stock Details ARVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.7M Hold
3,457,815
– – 16.24% 3
2026
Q1 		$34.9M Hold
3,457,815
– – 14.63% 3
2025
Q4 		$41M Hold
3,457,815
– – 17.34% 2
2025
Q3 		$29.5M Hold
3,457,815
– – 6.73% 4
2025
Q2 		$25.4M Hold
3,457,815
– – 4.42% 3
2025
Q1 		$24.3M Hold
3,457,815
– – 4.85% 4
2024
Q4 		$66.3M Buy
+3,457,815
New +$84M 2.56% 3

Other funds holding ARVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Pfizer's ARVN Position: Q2 2026 in Review

Pfizer held its Arvinas (ARVN) position steady in Q2 2026 at 3,457,815 shares worth $27.7M. The position accounts for 16.24% of the portfolio, ranked #3.

Pfizer first reported a position in ARVN in Q4 2024 and has held it in 7 quarters since. The position peaked at $66.3M in Q4 2024. 200 funds tracked by Wall St. Rank hold ARVN as of Q2 2026.

  • Pfizer held 3,457,815 shares of Arvinas worth $27.7M as of Q2 2026.
  • Pfizer left its Arvinas share count unchanged in Q2 2026.
  • Arvinas made up 16.24% of Pfizer's portfolio in Q2 2026, its #3 holding.
  • Pfizer first reported a position in Arvinas in Q4 2024 and has held it in 7 quarters since.
  • Pfizer's Arvinas position peaked at $66.3M in Q4 2024.
  • 200 funds tracked by Wall St. Rank held Arvinas as of Q2 2026.

Based on Pfizer's 13F filing for Q2 2026, filed 13 Aug 2026.